Search
Search titles only
By:
Search titles only
By:
Home
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
New posts
Search forums
Menu
Install the app
Install
Reply to Thread
Guest, we'd love to know what you think about the forum! Take the
Diabetes Forum Survey 2024 »
Home
Forums
Diabetes News and Research
Diabetes News
Lantus maker Sanofi buys inhaled insulin Afrezza
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="DCUK NewsBot" data-source="post: 610592" data-attributes="member: 106455"><p>French pharmaceutical firm Sanofi has bought the marketing rights to the new inhaled insulin, Afrezza. Afrezza is insulin in powder form that is inhaled rather than injected. The insulin, which has been developed by MannKind Corp., has recently been approved for marketing by the US Food and Drug Administration. Whilst Afrezza has been approved in the US, it is currently completing clinical trials for European approval. Under the deal, Sanofi will pay MannKind $150 million up front and, if the new insulin meets sales targets, MannKind could receive up to $775 million more. The deal, therefore, could be worth almost a billion dollars. The $925 million maximum works out as around £550 million. Sanofi is the manufacturer of the biggest selling insulin, Lantus; a long acting, analogue insulin that is used by people with type 1 and type 2 diabetes. Afrezza's benefits include not requiring injections and its ultra rapid action. The insulin has a peak activity between 12 and 15 minutes after inhalation. This is much quicker than injections of rapid acting insulin which has peak activity between 30 and 90 minutes after being injected. When tested in clinical trials, Afrezza was not able to achieve as good HbA1c levels in people with type 1 diabetes as rapid acting insulin injections. However, this may be explained to some degree by part the fact that patients taking Afrezza had lower rates of hypoglycemia.</p><p></p><p><strong><a href="http://www.diabetes.co.uk/news/2014/aug/lantus-maker-sanofi-buys-inhaled-insulin-afrezza-93305802.html" target="_blank">Continue reading...</a></strong></p></blockquote><p></p>
[QUOTE="DCUK NewsBot, post: 610592, member: 106455"] French pharmaceutical firm Sanofi has bought the marketing rights to the new inhaled insulin, Afrezza. Afrezza is insulin in powder form that is inhaled rather than injected. The insulin, which has been developed by MannKind Corp., has recently been approved for marketing by the US Food and Drug Administration. Whilst Afrezza has been approved in the US, it is currently completing clinical trials for European approval. Under the deal, Sanofi will pay MannKind $150 million up front and, if the new insulin meets sales targets, MannKind could receive up to $775 million more. The deal, therefore, could be worth almost a billion dollars. The $925 million maximum works out as around £550 million. Sanofi is the manufacturer of the biggest selling insulin, Lantus; a long acting, analogue insulin that is used by people with type 1 and type 2 diabetes. Afrezza's benefits include not requiring injections and its ultra rapid action. The insulin has a peak activity between 12 and 15 minutes after inhalation. This is much quicker than injections of rapid acting insulin which has peak activity between 30 and 90 minutes after being injected. When tested in clinical trials, Afrezza was not able to achieve as good HbA1c levels in people with type 1 diabetes as rapid acting insulin injections. However, this may be explained to some degree by part the fact that patients taking Afrezza had lower rates of hypoglycemia. [b][url="http://www.diabetes.co.uk/news/2014/aug/lantus-maker-sanofi-buys-inhaled-insulin-afrezza-93305802.html"]Continue reading...[/url][/b] [/QUOTE]
Verification
Post Reply
Home
Forums
Diabetes News and Research
Diabetes News
Lantus maker Sanofi buys inhaled insulin Afrezza
Top
Bottom
Find support, ask questions and share your experiences. Ad free.
Join the community »
This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies.
Accept
Learn More.…